Nutriband Inc.

Nutriband Inc.

NTRB·NASDAQ

$4.15

-0.72%
HealthcareBiotechnology

Nutriband Inc. develops a portfolio of transdermal pharmaceutical products. The company's lead product in development is AVERSA fentanyl, an abuse deterrent fentanyl transdermal system that provides clinicians and patients with an extended-release transdermal fentanyl product for use in managing chronic pain requiring around the clock opioid therapy. It also develops other products, which include AVERSA buprenorphine and AVERSA methylphenidate; exenatide for type 2 diabetes; and follicle stimulating hormone for infertility. Nutriband Inc. has a license agreement with Rambam Med-Tech Ltd. for the development of the RAMBAM Closed System Transfer Devices. The company was incorporated in 2016 and is headquartered in Orlando, Florida.

At a Glance

Live Snapshot
Market Cap$50.45M
EPS-0.9900
P/E Ratio-4.19
Earnings Date04/27/2026

ntrb

Stock Based Compensation

Last Annual Value

1.54M

3-Year CAGR

20%

5-Year CAGR

44%

10-Year CAGR

%

Nutriband Inc.

Nutriband Inc. Competitors Analysis of Stock Based Compensation

NTRB · NASDAQ
CompanyStock Based Compensation
CAGR 3Y
CAGR 5Y
CAGR 10Y
NTRB logo
Nutriband Inc.
NASDAQ:NTRB
1.54M
27.6%11.4%69.7% 
11.71M
31.0%36.0%N/A
0.00
N/AN/AN/A
XBIT logo
XBiotech Inc.
NASDAQ:XBIT
3.62M
3.6%-4.1%-4.2%
14.72M
8.2%96.9%N/A
ACET logo
Adicet Bio, Inc.
NASDAQ:ACET
14.27M
-11.0%2.7%N/A
1.80M
-17.9%16.5%N/A
445.00K
-38.8%-30.5%N/A
VXRT logo
Vaxart, Inc.
NASDAQ:VXRT
8.31M
-16.2%-1.3%15.9%
IMA logo
ImageneBio Inc
NASDAQ:IMA
15.39M
N/A24.3%N/A
IMUX logo
Immunic, Inc.
NASDAQ:IMUX
8.86M
7.7%8.3%6.6%
Nutriband Inc.

Nutriband Inc. Fair Value Envelope

NTRB · NASDAQ

Our analysis suggests that NTRB has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $4.15, this represents a potential HIDDEN relative to our calculated worth for Nutriband Inc..

Intrinsic Value
Current Price: $4.15